Tolemy Bio
Tolemy Bio is a company specializing in engineering cell performance through custom-designed cell culture media tailored for cell and gene therapy manufacturing processes. They provide personalized, process-specific media solutions for immune cell therapies (CAR-Ts, TILs, CAR-NKs), stem cell therapies (HSCs, MSCs, iPSCs), and gene therapies (HEK293 producing AAV & LVV). Their approach leverages AI, machine learning, and proprietary computational frameworks to rapidly develop optimized media formulations that enhance cell growth, endurance, and functionality. They offer small-batch scalable manufacturing for R&D and pre-clinical phases, with rigorous quality control and validation to meet critical quality attributes. Their business model includes milestone-based media licensing to minimize risk and support seamless translation from research to clinical and commercial success. Based in Cambridge, UK, Tolemy Bio positions itself as a key enabler for efficient manufacturing of advanced therapies with tailored media solutions integrated into existing processes.
Tolemy Bio
Tolemy Bio is a company specializing in engineering cell performance through custom-designed cell culture media tailored for cell and gene therapy manufacturing processes. They provide personalized, process-specific media solutions for immune cell therapies (CAR-Ts, TILs, CAR-NKs), stem cell therapies (HSCs, MSCs, iPSCs), and gene therapies (HEK293 producing AAV & LVV). Their approach leverages AI, machine learning, and proprietary computational frameworks to rapidly develop optimized media formulations that enhance cell growth, endurance, and functionality. They offer small-batch scalable manufacturing for R&D and pre-clinical phases, with rigorous quality control and validation to meet critical quality attributes. Their business model includes milestone-based media licensing to minimize risk and support seamless translation from research to clinical and commercial success. Based in Cambridge, UK, Tolemy Bio positions itself as a key enabler for efficient manufacturing of advanced therapies with tailored media solutions integrated into existing processes.